Sign In
Buy IONS
$73.82
+0.85 (+1.16%)
At Close: Jun 03, 2026
Ionis Pharmaceuticals, Inc. (IONS) CEO Brett Monia on Q4 2020 Results - Earnings Call Transcript
01:26pm, Wednesday, 24'th Feb 2021
Ionis Pharmaceuticals, Inc. (IONS) CEO Brett Monia on Q4 2020 Results - Earnings Call Transcript
Ionis Pharmaceuticals (IONS) Reports Q4 Loss, Tops Revenue Estimates
09:06am, Wednesday, 24'th Feb 2021
Ionis Pharmaceuticals (IONS) delivered earnings and revenue surprises of -1116.67% and 9.05%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the st
Ionis Pharmaceuticals: Q4 Earnings Insights
07:22am, Wednesday, 24'th Feb 2021
Shares of Ionis Pharmaceuticals (NASDAQ:IONS) remained unaffected after the company reported Q4 results. Quarterly Results Earnings per share fell 39.10% over the past year to $0.81, which beat the es
Ionis to present at upcoming investor conferences
07:05am, Friday, 19'th Feb 2021
CARLSBAD, Calif., Feb. 19, 2021 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS), the leader in RNA-targeted therapeutics, today announced that management will participate in a virtual fires
Analysts Estimate Ionis Pharmaceuticals (IONS) to Report a Decline in Earnings: What to Look Out for
01:40pm, Wednesday, 17'th Feb 2021
Ionis Pharmaceuticals (IONS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Ionis to hold 2020 financial results webcast
07:05am, Thursday, 11'th Feb 2021
CARLSBAD, Calif., Feb. 11, 2021 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) announced today that it will host a live webcast on Wednesday, February 24th at 9:00 a.m. Eastern Time to dis
Neurocrine, Ionis, Vertex: Underperforming Healthcare Stocks Poised To Recover
08:30am, Tuesday, 19'th Jan 2021
Our theme of Out Of Favor Health Care Stocks includes health care stocks that have witnessed strong Revenue growth and improving fundamentals over the last few years but have underperformed in 2020, o
Ionis appoints Eugene Schneider, M.D., as executive vice president and chief clinical development officer
05:30pm, Thursday, 07'th Jan 2021
CARLSBAD, Calif., Jan. 7, 2021 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) today announced the appointment of Eugene Schneider, M.D., as executive vice president and chief clinical deve
Ionis to present at 39th Annual J.P. Morgan Healthcare Conference
08:38pm, Tuesday, 05'th Jan 2021
CARLSBAD, Calif., Jan. 5, 2021 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS), the leader in RNA-targeted therapeutics, today announced that Brett P. Monia, Ph.D., chief executive officer,
BioMarin, Alkermes, Ionis: Are These Health Care Stocks Set To Outperform In 2021?
08:00am, Monday, 04'th Jan 2021
Our theme of Out Of Favor Health Care Stocks includes health care names that have witnessed strong growth and improving fundamentals over the last few years but have still underperformed over 2020, pa
Stanley T. Crooke, Ph.D., M.D, to retire from Ionis to focus on his scientific interests and n-Lorem Foundation
06:30pm, Thursday, 17'th Dec 2020
CARLSBAD, Calif., Dec. 17, 2020 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (NASDAQ: IONS), the leader in RNA-targeted therapeutics, announced today that its founder and executive chairman Stanley T.
Ionis highlights achievements, commercial strategy and technology advancements at Investor Day
09:15pm, Tuesday, 08'th Dec 2020
CARLSBAD, Calif., Dec. 8, 2020 /PRNewswire/ -- At its Investor Day yesterday, Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) highlighted the company's significant achievements in 2020 and outlined its str
Ionis to participate in virtual fireside chat at BMO 2020 Growth and ESG conference
07:05am, Wednesday, 02'nd Dec 2020
CARLSBAD, Calif., Dec. 2, 2020 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS), the leader in antisense therapeutics, today announced that management will participate in a virtual fireside
CARLSBAD, Calif., Dec. 1, 2020 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) today announced the initiation of the Phase 3 BALANCE study for AKCEA-APOCIII-LRx in adult patients with famil
Ionis to hold virtual investor day event
07:05am, Tuesday, 01'st Dec 2020
CARLSBAD, Calif., Dec. 1, 2020 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) announced today that it will host a live investor day webcast on Monday, December 7th at 11:00 a.m. Eastern Ti
